Ginkgo Bioworks DNA
$7.46 −$0.74 (-9.02%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $7.55 +1.21%
Open$7.93
Prev close$8.20
Day range$7.38 – $8.29
Volume2.51M
Market cap$483.59M
P/E (TTM)–
Dividend yield–
Earnings
Average move on report day±9.7%last 16 reports
Closed higher4 of 1625% of the time
Best reaction+14.7%
Worst reaction-30.5%
Stock move on the day after each report
| Quarter | Report date | Timing | Implied move | Actual move | Versus implied |
|---|---|---|---|---|---|
| 2026/Q3 | 5 Nov 2026 | After Market | ±20.9% | +13.35% | Within range |
| 2026/Q2 | 5 Aug 2026 | After Market | ±15.7% | -9.29% | Within range |
| 2026/Q1 | 7 May 2026 | After Market | ±16.6% | -13.47% | Within range |
| 2025/Q4 | 26 Feb 2026 | After Market | ±20.4% | -30.48% | Bigger than priced |
| 2025/Q3 | 6 Nov 2025 | After Market | ±18.8% | -20.80% | Bigger than priced |
| 2025/Q2 | 7 Aug 2025 | After Market | ±20.6% | -8.69% | Within range |
| 2025/Q1 | 6 May 2025 | After Market | ±23.8% | +14.73% | Within range |
| 2024/Q4 | 25 Feb 2025 | After Market | ±30.7% | -11.47% | Within range |
| 2024/Q3 | 12 Nov 2024 | After Market | ±23.1% | +2.50% | Within range |
| 2024/Q2 | 8 Aug 2024 | After Market | ±101.5% | -5.46% | Within range |
| 2023/Q3 | 8 Nov 2023 | Pre Market | ±30.1% | -3.25% | Within range |
| 2023/Q2 | 9 Aug 2023 | After Market | ±21.4% | -12.94% | Within range |
| 2023/Q1 | 10 May 2023 | Pre Market | ±26.5% | -1.46% | Within range |
| 2022/Q4 | 1 Mar 2023 | After Market | ±30.1% | +0.00% | Within range |
| 2022/Q3 | 14 Nov 2022 | After Market | ±25.6% | -0.37% | Within range |
| 2022/Q2 | 15 Aug 2022 | After Market | ±21.5% | +7.16% | Within range |
"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$27.71M-5.7% YoY
Operating profit-$43.63M+46.5% YoY
Net profit-$40.98M+49.2% YoY
Diluted EPS-$0.64+55.9% YoY
Free cash flow-$30.35M+4.0% YoY
Operating cash flow-$28.35M
Revenue, last 8 quarters
Net profit, last 8 quarters
Profitability & balance sheet
Gross margin69.8%
Operating margin-202.5%
Net margin-192.0%
Return on equity-52.7%
Return on assets-23.5%
Return on invested capital-30.0%
Current ratio4.72
Liabilities / assets58.4%
Cash & investments$285.36M
Total debt$397.20M
Net cash (debt)-$111.84M
No comments yet — be the first to weigh in on DNA.
Sign in to join the discussion.